NCT00145431

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia).

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

Detailed description

For additional information please call: 1-800-718-1021

Conditions

• Hyperlipoproteinemia Type III

Interventions

Type	Name	Description
DRUG	torcetrapib/atorvastatin
DRUG	atorvastatin
DRUG	fenofibrate

Timeline

• Start date: 2005-03-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2005-09-05
• Last updated: 2012-02-17

Locations

27 sites across 2 countries: United States, Canada